PT-141
Bremelanotide · Vyleesi
A synthetic melanocortin receptor agonist that acts on central pathways involved in sexual arousal. FDA-approved as Vyleesi and studied for hypoactive sexual desire disorder in premenopausal women.
Half-life
~2.7 h terminal (range 1.9-4.0 h), subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Lyophilized powder kept cool, dry and away from light; once reconstituted, kept refrigerated.
References
- FDA label: Vyleesi (2019)
Related in Sexual / Hormonal
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.